Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | (1) | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Insmed Inc | INSM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 25.81 | 05:45:19 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 25.81 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 18.085 - 32.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 25.81 | USD |
Insmed (INSM) Options Flow Summary
Insmed Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 3.83B | 148.49M | - | 305.21M | -749.57M | -5.05 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Insmed News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INSM Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 26.07 | 26.31 | 23.525 | 24.73 | 3,196,255 | -0.26 | -1.00% |
| 1 Month | 27.22 | 28.71 | 23.525 | 26.21 | 2,167,514 | -1.41 | -5.18% |
| 3 Months | 28.02 | 29.91 | 23.525 | 27.08 | 1,772,406 | -2.21 | -7.89% |
| 6 Months | 24.90 | 32.00 | 23.04 | 27.15 | 1,671,734 | 0.91 | 3.65% |
| 1 Year | 18.78 | 32.00 | 18.085 | 25.16 | 1,441,908 | 7.03 | 37.43% |
| 3 Years | 35.50 | 36.97 | 16.04 | 23.75 | 1,212,164 | -9.69 | -27.30% |
| 5 Years | 30.83 | 45.44 | 12.09 | 24.81 | 1,140,537 | -5.02 | -16.28% |
Insmed Description
| Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension. |
